126 related articles for article (PubMed ID: 19353351)
1. Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients.
Johnson M; Agusti AG; Barnes NC
COPD; 2008 Dec; 5(6):369-75. PubMed ID: 19353351
[TBL] [Abstract][Full Text] [Related]
2. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
Calverley PM; Anderson JA; Celli B; Ferguson GT; Jenkins C; Jones PW; Yates JC; Vestbo J;
N Engl J Med; 2007 Feb; 356(8):775-89. PubMed ID: 17314337
[TBL] [Abstract][Full Text] [Related]
3. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
[TBL] [Abstract][Full Text] [Related]
4. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study.
Jenkins CR; Jones PW; Calverley PM; Celli B; Anderson JA; Ferguson GT; Yates JC; Willits LR; Vestbo J
Respir Res; 2009 Jun; 10(1):59. PubMed ID: 19566934
[TBL] [Abstract][Full Text] [Related]
6. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease.
Hoshino M; Ohtawa J
Respirology; 2011 Jan; 16(1):95-101. PubMed ID: 20920142
[TBL] [Abstract][Full Text] [Related]
7. TORCH and UPLIFT: what has been learned from the COPD "mega-trials"?
Niewoehner DE
COPD; 2009 Feb; 6(1):1-3. PubMed ID: 19229702
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
Tonnel AB; Tillie-Leblond I; Attali V; Bavelele Z; Lagrange O
Respir Med; 2011 Feb; 105(2):250-8. PubMed ID: 20702076
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
Oba Y
Am J Manag Care; 2009 Apr; 15(4):226-32. PubMed ID: 19355795
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
Earnshaw SR; Wilson MR; Dalal AA; Chambers MG; Jhingran P; Stanford R; Mapel DW
Respir Med; 2009 Jan; 103(1):12-21. PubMed ID: 19010652
[TBL] [Abstract][Full Text] [Related]
11. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
Singh D; Brooks J; Hagan G; Cahn A; O'Connor BJ
Thorax; 2008 Jul; 63(7):592-8. PubMed ID: 18245142
[TBL] [Abstract][Full Text] [Related]
12. Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease.
Keating GM; McCormack PL
Drugs; 2007; 67(16):2383-405. PubMed ID: 17983257
[TBL] [Abstract][Full Text] [Related]
13. COPD: don't use fluticasone + salmeterol. Patients treated with inhaled fluticasone for chronic obstructive pulmonary disease (COPD) are more prone to pneumonia.
Prescrire Int; 2007 Dec; 16(92):257-8. PubMed ID: 18092426
[No Abstract] [Full Text] [Related]
14. Effects of salmeterol and fluticasone propionate combination versus fluticasone propionate on airway function and eosinophilic inflammation in mild asthma.
Hoshino M; Handa H; Miyazawa T
Allergol Int; 2009 Sep; 58(3):357-63. PubMed ID: 19454840
[TBL] [Abstract][Full Text] [Related]
15. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.
Tashkin DP
Am J Med; 2006 Oct; 119(10 Suppl 1):63-72. PubMed ID: 16996901
[TBL] [Abstract][Full Text] [Related]
16. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
Schermer TR; Albers JM; Verblackt HW; Costongs RJ; Westers P
Fam Pract; 2007 Apr; 24(2):181-8. PubMed ID: 17251178
[TBL] [Abstract][Full Text] [Related]
17. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.
Crim C; Calverley PM; Anderson JA; Celli B; Ferguson GT; Jenkins C; Jones PW; Willits LR; Yates JC; Vestbo J
Eur Respir J; 2009 Sep; 34(3):641-7. PubMed ID: 19443528
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study.
Make B; Hanania NA; ZuWallack R; Kalberg C; Emmett A; Brown CP; Knobil K
Clin Ther; 2005 May; 27(5):531-42. PubMed ID: 15978302
[TBL] [Abstract][Full Text] [Related]
19. [Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial].
Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
Rev Port Pneumol; 2005; 11(6):587-9. PubMed ID: 16514718
[No Abstract] [Full Text] [Related]
20. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study.
Ferguson GT; Calverley PMA; Anderson JA; Jenkins CR; Jones PW; Willits LR; Yates JC; Vestbo J; Celli B
Chest; 2009 Dec; 136(6):1456-1465. PubMed ID: 19581353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
